{"name":"PDS Biotechnology Corp.","slug":"pds-biotechnology-corp","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Pembrolizumab Monotherapy","genericName":"Pembrolizumab Monotherapy","slug":"pembrolizumab-monotherapy","indication":"Melanoma (unresectable or metastatic)","status":"phase_3"}]}],"pipeline":[{"name":"Pembrolizumab Monotherapy","genericName":"Pembrolizumab Monotherapy","slug":"pembrolizumab-monotherapy","phase":"phase_3","mechanism":"Pembrolizumab is a monoclonal antibody that blocks PD-1 on T cells, allowing the immune system to recognize and attack cancer cells.","indications":["Melanoma (unresectable or metastatic)","Non-small cell lung cancer (metastatic, PD-L1 positive)","Head and neck squamous cell carcinoma (recurrent or metastatic)","Hodgkin lymphoma (relapsed or refractory)","Urothelial carcinoma (locally advanced or metastatic)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQejhCYjJabGZtcFd4UG8tc0R3SzBVZ3Y5OFVsSXVRNkYwam11bmNUMnZuaHAtTjNBYTc4c3RKSG4zRU5ZTXJPQTRHenZDUTJOUno4YXMybFYzakxiSFRoYUhzUzFjbjhmU2hxRTNhQS1QZ2ZmUW1OZjdZcVBMR0tfVHdMZXdNME5nVzZTRVNFN3ZVZDR6R2hYSmVB?oc=5","date":"2026-03-30","type":"earnings","source":"Benzinga","summary":"Earnings Scheduled For March 30, 2026 - Benzinga","headline":"Earnings Scheduled For March 30, 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9pUl9mX3hGVXk3MXRISDZzVnpVbTZJTWlHdnhvUjRGQ3I2NzhJZUY4UzdqbXFuUU5DU3dKd1NvSnFvWHc4RFY1MDRucmhUREQxLXN1dkdObzBZMFlhUjdZR0U1TVBsSThoMmdzaU5R?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Fibrogen Inc (FGEN) - Stock Titan","headline":"If You Invested $1,000 in Fibrogen Inc (FGEN)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-12","type":"pipeline","source":"GlobeNewswire","summary":"Pharmaceutical and Biotechnology Royalty Rates Agreements - GlobeNewswire","headline":"Pharmaceutical and Biotechnology Royalty Rates Agreements","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNcVVjbmI5Y3BoaU13aTNJS2dOXzZqNmstN1pMSEtTak9xT0VlYkV4UExYYldVT1YzUkFLSEduTkVJMG10a0o4amc1Zko3eGRJcWVuUGJIMGJpM210WG9iUHk1ZFlfcnhzbWNqWUJJbTdrRzUwR0lQLTczZ0MzZjRsZ3kxcnc2bUhfQjl0bVJmTXJkaV9adE4yU0RXLWNiSkw3RHlUNXRqMmNONU1KQ2RIdGtKb193YVVY?oc=5","date":"2026-02-20","type":"trial","source":"Stock Titan","summary":"Cancer trial shift seeks faster PDS0101 bid for HPV16 head and neck patients - Stock Titan","headline":"Cancer trial shift seeks faster PDS0101 bid for HPV16 head and neck patients","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE1adVV0T0x6NUszaThvNjZWZ1ZPamVodFNhOVdCSk9aNDRVc0pzWjZ2bXlkU0k5Nk95a3FnOUlQQTItcGZ1SmJPeFJlV2puQ1hxWVVCX2VUcjRBd0Uw?oc=5","date":"2026-02-09","type":"trial","source":"Finimize","summary":"PDS Biotech’s Big Bet Rides On Two Trial Readouts - Finimize","headline":"PDS Biotech’s Big Bet Rides On Two Trial Readouts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOa0NYVElKRWJ5blZCQ0FoNFgyWTNUS1AtR2U5Rmc4WVljaFJ5RWhza0Q4VVpic2RGX1REQjFETnBwMXB4d0F0aTRsYXBTdk5IYWVyWUxQN3FGLVdCU1dYX2cxa2VmbzRBdVg0c0JyT3lubHdmTE9ibFMwem1paUtyVGpwTG1pT0VIU25WZ0lWMnJ1bUhFTWhLOUtjTktfc19sY2FMc3U0Mk9TU0JrVnU3Tm13T0dReS0y?oc=5","date":"2026-01-09","type":"trial","source":"Stock Titan","summary":"Cancer trial tweak could get a new head and neck treatment to patients faster - Stock Titan","headline":"Cancer trial tweak could get a new head and neck treatment to patients faster","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxOUk1VSzNEbzVFYmdWeEh5RjRvX2ZzUTRGVkhvaFFCSzBQT3NuNVJnSDI4dEpLUWl5M3hTeXhjeFhBcmN6ZWp2ZUlFano4ZVdpMEg3S2hiMEtseUtyaldfWXZhUk9RYzFGQ0FnaXZEMHk2LTh6Q0hpZk9XYnBtTjNVam9aNmtzb0ZTMTRMUXBCWVcya2NtdmNzeWtQTkVNYW9CRGNqNjBDNjNqMVBZTU85NzNuWi04RmdvTE1nREZDd1hKMXZoU1ByYy05bkcwVUN3enVKUFVmOHFwWG1DM200aFRfOHNYTy1wQmVj?oc=5","date":"2025-08-14","type":"pipeline","source":"Finansavisen","summary":"Biotech Stocks Rally as Oncology Market Targets $866B by 2034 - Finansavisen","headline":"Biotech Stocks Rally as Oncology Market Targets $866B by 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1sLUMzT0xkcFN3T1FQa29PdVVXaDNuUzgwa19PbktyT3A0Mk5udWlKcG5hb2lPVjAyamEwRGR6ektiX3M3ODlyWUkycTBBRHA5Vm00?oc=5","date":"2025-07-22","type":"pipeline","source":"Stock Titan","summary":"LIMN Stock Price, News & Analysis - Stock Titan","headline":"LIMN Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTFBSTHpHVTlaZ3pkLU1fSnJXTVNzY1otdEhsa1lxX2gyZ1VvUnpadGw0bk1naEg1Q2xuZjJCc3pJNS1vTnVyNmliYlBjSVB5MTVKcnM2b3lnTDlwWmd6cXZha1hWc0lOWTlp?oc=5","date":"2024-07-01","type":"pipeline","source":"The Pharma Letter","summary":"PDS Biotech - The Pharma Letter","headline":"PDS Biotech","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxORDB4cVVUcW85NFEyYks4QndmdU8taWtKYUdWVlNmNVJwbXdMSXlVMktSanNXeV90SExQN2RuWUxUSU9YOTdHR19GMmFtTVhUN2duZFlRMUlzdFJ0c0trd1Y1VThEQTV6eGRqdDJHQ1RwZjJoQ0RmLWhZeVp5dFV1MDJVd2pDNUZocjFLaDBWbW5CdlI2YU5DY1FKUVQzNlNrNEoyeA?oc=5","date":"2024-05-02","type":"pipeline","source":"citybiz","summary":"PDS Biotech Appoints Stephan Toutain as Chief Operating Officer - citybiz","headline":"PDS Biotech Appoints Stephan Toutain as Chief Operating Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxPdXdBRnZ6STdHYWRHZVB5dGJnYzFXTXlHWkphQWlwQ3VBNWVMT0FRSGpNZENzYWpGUHhGTVN5Qk90NC1qQ0tGay1SdXdPQUNBRHZJOGRvUVdfWG50X2FOaWVNemJ6RkJnOE95clM0dElZb2Z2U2FmbWFaOTRJVmdtaTR2UWpldw?oc=5","date":"2024-03-13","type":"deal","source":"Yahoo Finance","summary":"The 3 Most Undervalued Biotech Stocks to Buy in March 2024 - Yahoo Finance","headline":"The 3 Most Undervalued Biotech Stocks to Buy in March 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTE5CaU1wcm91ZkNELVZobWdsUGRiQmtaZmREUTRiVDRTdUR5TDIzM0Qzb21VMkVzWVBjcmJ2b2h4a3JoMk9HNW1abk5xWUNCWFpYX1E?oc=5","date":"2019-04-21","type":"pipeline","source":"Yahoo! Finance Canada","summary":"PDS Biotechnology Corporation (PDSB) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"PDS Biotechnology Corporation (PDSB) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}